For people who actually need it for hypotrichosis, I'm sure this new product is welcome. However, I suspect most users will acquire this drug purely for cosmetic enhancement of normal eyelashes. Read more below or see full article here.
Allergan Inc. will be able to sell its Lumigan glaucoma drug for cosmetic use now that the Food and Drug Administration has approved the product to enhance eyelashes.
The company, which also makes Botox, will market the product under the brand name Latisse for hypotrichosis, a condition in which there are not enough eyelashes. Allergan plans a first-quarter launch for Latisse, which will be available by prescription.
The once-daily product is the first FDA-approved drug sold for eyelash enhancement as measured by increases in eyelash length, thickness and darkness.
Available only through a doctor, LATISSE(TM) is a once-daily prescription treatment applied to the base of the upper eyelashes with a sterile, single-use-per-eye disposable applicator. LATISSE(TM) users can expect to experience longer, fuller and darker eyelashes in as little as eight weeks, with full results in 16 weeks. To maintain effect, continued treatment with LATISSE(TM) is required. If use of LATISSE(TM) is discontinued, eyelashes will gradually return to where they were prior to treatment over a period of weeks to months (average eyelash hair cycle).
Important LATISSE™ Safety Information
LATISSE™ solution is intended for use on the skin of the upper eyelid margins at the base of the eyelashes. DO NOT APPLY to the lower eyelid. If you are using LUMIGAN® or other products in the same class for elevated intraocular pressure (IOP), or if you have a history of abnormal IOP, you should only use LATISSE™ under the close supervision of your doctor.
LATISSE™ use may cause darkening of the eyelid skin which may be reversible. Although not reported in clinical studies, LATISSE™ use may also cause increased brown pigmentation of the colored part of the eye which is likely to be permanent.
It is possible for hair growth to occur in other areas of your skin that LATISSE™ frequently touches. Any excess solution outside the upper eyelid margin should be blotted with a tissue or other absorbent material to reduce the chance of this from happening. It is also possible for a difference in eyelash length, thickness, fullness, pigmentation, number of eyelash hairs, and/or direction of eyelash growth to occur between eyes. These differences, should they occur, will usually go away if you stop using LATISSE™.
The most common side effects after using LATISSE™ solution are an itching sensation in the eyes and/or eye redness. This was reported in approximately 4% of patients. LATISSE™ solution may cause other less common side effects which typically occur on the skin close to where LATISSE™ is applied, or in the eyes. These include skin darkening, eye irritation, dryness of the eyes, and redness of the eyelids.
If you develop a new ocular condition (e.g., trauma or infection), experience a sudden decrease in visual acuity, have ocular surgery, or develop any ocular reactions, particularly conjunctivitis and eyelid reactions, you should immediately seek your doctor’s advice concerning the continued use of LATISSE™ solution.
Full prescribing information is available at www.latisse.com and www.allergan.com.
Filed Under (tags):
- dave's blog
- Log in or register to post comments